Synthesis, spectral characterization, and biochemical evaluation of antidiabetic properties of a new zinc-diosmin complex studied in high fat diet fed-low dose streptozotocin induced experimental type 2 diabetes in rats

Biochemistry Research International

Volumn 2015, Issue , 2015, Pages

  Gopalakrishnan, Veerasamy ^a   Iyyam Pillai, Subramanian ^b   Subramanian, Sorimuthu Pillai ^a  

^a UNIVERSITY OF MADRAS   (India)

^b PACHAIYAPPA S COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84953237530     PISSN: 20902247     EISSN: 20902255     Source Type: Journal    
DOI: 10.1155/2015/350829     Document Type: Article

References (74)

1. S. Panda and A. Kar, Antidiabetic and antioxidative effects of Annona squamosa leaves are possibly mediated through quercetin-3-O-glucoside, BioFactors, vol. 31, no. 3-4, pp. 201-210, 2007.
2. M. E. Cerf, Beta cell dysfunction and insulin resistance, Frontiers in Endocrinology, vol. 4, article 37, 2013.
3. L. Guariguata, D. R. Whiting, I. Hambleton, J. Beagley, U. Linnenkamp, and J. E. Shaw, Global estimates of diabetes prevalence for 2013 and projections for 2035, Diabetes Research and Clinical Practice, vol. 103, no. 2, pp. 137-149, 2014.
4. N. S. Levitt, J. M. Katzenellenbogen, D. Brabshaw, M. N. Hoffman, and F. Bonnici, The prevalence and identification of risk factors for NIDDMin urban Africans in Cape Town, South Africa, Diabetes Care, vol. 16, no. 4, pp. 601-607, 1993.
5. R. Herring, R. H. Jones, and D. L. Russell-Jones, Hepatoselectivity and the evolution of insulin, Diabetes, Obesity and Metabolism, vol. 16, no. 1, pp. 1-8, 2014.
6. J. Mukai, H. Tada, Y. Watanabe et al., Lipids behavior and adverse effects for oral antidiabetic agents in patients with type2 diabetes treated with sulfonylureas alone based on systematic review, Yakugaku Zasshi, vol. 127, no. 10, pp. 1747-1756, 2007.
7. A. Katoh, Y. Matsumura, Y. Yoshikawa, H. Yasui, and H. Sakurai, Evaluation of insulin-mimetic activities of vanadyl and zinc(II) complexes from the viewpoint of heterocyclic bidentate ligands, Journal of Inorganic Biochemistry, vol. 103, no. 4, pp. 567-574, 2009.
8. A. R. Marita and K. L. Anilkumar, Effect of vanadate on glycogen synthesis in dexamethasone-treated 3T3 adipocytes: evidence for a novel insulin sensitizing action, Diabetes, Obesity and Metabolism, vol. 3, no. 4, pp. 271-278, 2001.
9. M. C. Munoz, A. Barbera, J. Dominguez, J. Fernandez-Alvarez, R. Gomis, and J. J. Guinovart, Effects of tungstate, a new potential oral antidiabetic agent, in Zucker diabetic fatty rats, Diabetes, vol. 50, no. 1, pp. 131-138, 2001.
10. H. Sakurai, The discovery of vanadyl and zinc complexes for treating diabetes and metabolic syndromes, Expert Opinion on Drug Discovery, vol. 2, no. 6, pp. 873-887, 2007.
11. J. Meyerovitch, Z. Farfel, J. Sack, and Y. Shechter, Oral administration of vanadate normalizes blood glucose levels in streptozotocin-treated rats. Characterization and mode of action,The Journal of Biological Chemistry, vol. 262, no. 14, pp. 6658-6662, 1987.
12. R. Jayawardena, P. Ranasinghe, P. Galappatthy, R. L. D. K. Malkanthi, G. R. Constantine, and P. Katulanda, Effects of zinc supplementation on diabetes mellitus: a systematic review andmeta-analysis,Diabetology andMetabolic Syndrome, vol. 4, article 13, 2012.
13. D. A. Scott, Crystalline insulin, Biochemical Journal, vol. 28, no. 4, pp. 1592-1602.1, 1934.
14. L. Coulston and P. Dandona, Insulin-like effect of zinc on adipocytes, Diabetes, vol. 29, no. 8, pp. 665-667, 1980.
15. S. Frassinetti, G. L. Bronzetti, L. Caltavuturo, M. Cini, and C. D. Croce, The role of zinc in life: a review, Journal of Environmental Pathology, Toxicology and Oncology, vol. 25, no. 3, pp. 597-610, 2006.
16. B. L. Vallee and K. H. Falchuk, The biochemical basis of zinc physiology, Physiological Reviews, vol. 73, no. 1, pp. 79-118, 1993.
17. S. O. Emdin, G. G. Dodson, J. M. Cutfield, and S. M. Cutfield, Role of zinc in insulin biosynthesis. Some possible zinc-insulin interactions in the pancreatic B-cell, Diabetologia, vol. 19, no. 3, pp. 174-182, 1980.
18. D. Ozcelik, M. Naziroglu, M. Tuncdemir, O. Celik, M. Ozturk, and M. F. Flores-Arce, Zinc supplementation attenuates metallothionein and oxidative stress changes in kidney of streptozotocin-induced diabetic rats, Biological Trace Element Research, vol. 150, no. 1-3, pp. 342-349, 2012.
19. Y. Liu, B. Batchuluun, L. Ho et al., Characterization of zinc influx transporters (ZIPs) in pancreatic β cells, Journal of Biological Chemistry, vol. 290, no. 30, pp. 18757-18769, 2015.
20. Y. V. Li, Zinc and insulin in pancreatic beta-cells, Endocrine, vol. 45, no. 2, pp. 178-189, 2014.
21. M. Galanski, M. A. Jakupec, and B. K. Keppler, Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches, Current Medicinal Chemistry, vol. 12, no. 18, pp. 2075-2094, 2005.
22. E. J. Corey, M. M. Mehrotra, and A. U. Khan, Antiarthritic gold compounds effectively quench electronically excited singlet oxygen, Science, vol. 236, no. 4797, pp. 68-69, 1987.
23. Y. Yoshikawa, Development research of new Zn complexes with anti-diabetic effect-structure-activity-related studies by displacement of coordination atom, Yakugaku Zasshi, vol. 132, no. 9, pp. 1051-1055, 2012.
24. H. Sakurai and Y. Adachi, The pharmacology of the insulinomimetic effect of zinc complexes, BioMetals, vol. 18, no. 4, pp. 319-323, 2005.
25. K. Vijayaraghavan, S. I. Pillai, and S. P. Subramanian, Design, synthesis and characterization of zinc-3 hydroxy flavone, a novel zinc metallo complex for the treatment of experimental diabetes in rats, European Journal of Pharmacology, vol. 680, no. 1-3, pp. 122-129, 2012.
26. V. Sendrayaperumal, S. Iyyam Pillai, and S. Subramanian, Design, synthesis and characterization of zinc-morin, a metal flavonol complex and evaluation of its antidiabetic potential in HFD-STZ induced type 2 diabetes in rats, Chemico-Biological Interactions, vol. 219, pp. 9-17, 2014.
27. J. Uma Maheswari, S. Iyyam Pillai, and S. P. Subramanian, Zinc-silibinin complex: synthesis, spectral characterization and biochemical evaluation of antidiabetic potential in high fat fed low dose STZ induced type 2 diabetic rats, Journal of Chemical and Pharmaceutical Research, vol. 7, no. 3, pp. 2051-2064, 2015.
28. B. H. Havsteen, The biochemistry and medical significance of the flavonoids, Pharmacology andTherapeutics, vol. 96, no. 2-3, pp. 67-202, 2002.
29. C. A. Rice-Evans, N. J. Miller, and G. Paganga, Structureantioxidant activity relationships of flavonoids and phenolic acids, Free Radical Biology andMedicine, vol. 20, no. 7, pp. 933-956, 1996.
30. J. P. Cornard and J. C. Merlin, Comparison of the chelating power of hydroxyflavones, Journal of Molecular Structure, vol. 651-653, pp. 381-387, 2003.
31. M. A. Campanero, M. Escolar, G. Perez, E. Garcia-Quetglas, B. Sadaba, and J. R. Azanza, Simultaneous determination of diosmin and diosmetin in human plasma by ion trap liquid chromatography-atmospheric pressure chemical ionization tandem mass spectrometry: application to a clinical pharmacokinetic study, Journal of Pharmaceutical and Biomedical Analysis, vol. 51, no. 4, pp. 875-881, 2010.
32. O. A. Oesterle and G. Wander, Naturally occurring flavonic glycoside; rhamnoglycoside of diosmetin, q. v. Isolation from various plant sources, Helvetica Chimica Acta, vol. 8, article 519, 1925.
33. G. Hitzenberger, Therapeutic effectiveness of flavonoids illustrated by daflon 500mg, Wiener Medizinische Wochenschrift, vol. 147, no. 18, pp. 409-412, 1997.
34. W. Thanapongsathorn and T. Vajrabukka, Clinical trial of oral diosmin (Daflon) in the treatment of hemorrhoids, Diseases of the Colon and Rectum, vol. 35, no. 11, pp. 1085-1088, 1992.
35. A. K. Ratty and N. P. Das, Effects of flavonoids on nonenzymatic lipid peroxidation: structure-activity relationship, Biochemical Medicine and Metabolic Biology, vol. 39, no. 1, pp. 69-79, 1988.
36. T. Tanaka, H. Kohno, and H. Mori, Chemoprevention of colon carcinogenesis by dietary non-nutritive compounds, Asian Pacific Journal of Cancer Prevention, vol. 2, no. 3, pp. 165-177, 2001.
37. M. Tahir, M. U. Rehman, A. Lateef et al., Diosmin protects against ethanol-induced hepatic injury via alleviation of inflammation and regulation of TNF-α and NF-κB activation, Alcohol, vol. 47, no. 2, pp. 131-139, 2013.
38. S. Srinivasan and L. Pari, Ameliorative effect of diosmin, a citrus flavonoid against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats, Chemico-Biological Interactions, vol. 195, no. 1, pp. 43-51, 2012.
39. J. P. Cornard, L. Vrielynck, J. C. Merlin, and J. C. Wallet, Structural and vibrational study of 3-hydroxyflavone and 3-methoxyflavone, Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy, vol. 51, no. 5, pp. 913-923, 1995.
40. H.-X. Zhang and P. Mei, Synthesis of morin-zinc(II) complex and its interaction with serum albumin, Biological Trace Element Research, vol. 143, no. 2, pp. 677-687, 2011.
41. J. Tan, B. Wang, and L. Zhu, DNA binding, cytotoxicity, apoptotic inducing activity, and molecular modeling study of quercetin zinc(II) complex, Bioorganic and Medicinal Chemistry, vol. 17, no. 2, pp. 614-620, 2009.
42. N. E. Ikeda, E. M. Novak, D. A. Maria, A. S. Velosa, and R. M. Pereira, Synthesis, characterization and biological evaluation of Rutin-zinc(II) flavonoid-metal complex, Chemico-Biological Interactions, vol. 239, pp. 184-191, 2015.
43. K. H. Thompson, B. D. Liboiron, Y. Sun et al., Preparation and characterization of vanadyl complexes with bidentate maltoltype ligands; in vivo comparisons of anti-diabetic therapeutic potential, Journal of Biological Inorganic Chemistry, vol. 8, no. 1-2, pp. 66-74, 2003.
44. Z. Vargova, J. Kotek, J. Rudovsky et al., Ternary complexes of zinc(II), cyclen and pyridinecarboxylic acids, European Journal of Inorganic Chemistry, no. 25, pp. 3974-3987, 2007.
45. K. Srinivasan, B. Viswanad, L. Asrat, C. L. Kaul, and P. Ramarao, Combination of high-fat diet-fed and low-dose streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening, Pharmacological Research, vol. 52, no. 4, pp. 313-320, 2005.
46. E. Bartoli, G. P. Fra, and G. P. C. Schianca, The oral glucose tolerance test (OGTT) revisited, European Journal of Internal Medicine, vol. 22, no. 1, pp. 8-12, 2011.
47. D. R. Matthews, J. P. Hosker, A. S. Rudenski, B. A. Naylor, D. F. Treacher, and R. C. Turner, Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man, Diabetologia, vol. 28, no. 7, pp. 412-419, 1985.
48. W. Hassid and S. Abraham, Chemical procedures for analysis of polysaccharides, inMethods in Enzymology, S. Colowick and N. Kaplan, Eds., vol. 3, pp. 34-36, Academic Press, New York, NY, USA, 1957.
49. P. Trinder, Determination of blood glucose using an oxidaseperoxidase system with a non-carcinogenic chromogen, Journal of Clinical Pathology, vol. 22, no. 2, pp. 158-161, 1969.
50. S. S. Nayak and T. N. Pattabiraman, Anewcolorimetric method for the estimation of glycosylated hemoglobin, Clinica Chimica Acta, vol. 109, no. 3, pp. 267-274, 1981.
51. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall, Protein measurement with the Folin phenol reagent, The Journal of Biological Chemistry, vol. 193, no. 1, pp. 265-275, 1951.
52. M. L. Scott and C. Beffa, A rapid method for the estimation of urea in biologic fluids, American Journal of Clinical Ppathology, vol. 21, no. 3, pp. 275-281, 1951.
53. J. Brod and J. H. Sirota, The renal clearance of endogenous creatinine in man, Journal of Clinical Investigation, vol. 27, no. 5, pp. 645-654, 1948.
54. J. King, Transaminases: alanine and aspartate transaminases, in Practical Clinical Enzymology, pp. 363-395, D. Van Nostrand Company, London, UK, 1965.
55. J. King, The hydrolases-acid and alkaline phosphatases, in Practical Clinical Enzymology, pp. 199-208, D. Van Nostrand Company, London, UK, 1965.
56. L. F. Leloir and S. H. Goldemberg, Glycogen synthetase from rat liver, in Methods in Enzymology, S. P. Colowick and N. O. Kaplan, Eds., vol. 5, pp. 145-146, Academic Press, NewYork, NY, USA, 1962.
57. M. Cornblath, P. J. Randle, A. Parmeggiani, and H. E. Morgan, Regulation of glycogenolysis inmuscle. Effects of glucagon and anoxia on lactate production, glycogen content, and phosphorylase activity in the perfused isolated rat heart, The Journal of Biological Chemistry, vol. 238, pp. 1592-1597, 1963.
58. M. L. Godino-Salido, M. D. Gutierrez-Valero, R. Lopez-Garzon, and J. M. Moreno-Sanchez, Zn(II) complexes with thiopyrimidine derivatives: solution study, synthesis and crystal structure of a zig-zag chain zinc(II) complex with the ligand 4, 6-dimethyl-2-thiopyrimidine, Inorganica Chimica Acta, vol. 221, no. 1-2, pp. 177-181, 1994.
59. J.-S. Choi, J. J. Braymer, S. K. Park, S. Mustafa, J. Chae, and M. H. Lim, Synthesis and characterization of IMPY derivatives that regulate metal-induced amyloid-β aggregation, Metallomics, vol. 3, no. 3, pp. 284-291, 2011.
60. J. J. Braymer, J.-S. Choi, A. S. Detoma et al., Development of bifunctional stilbene derivatives for targeting and modulating metal-amyloid-β species, Inorganic Chemistry, vol. 50, no. 21, pp. 10724-10734, 2011.
61. V. G. Yuen, P. Caravan, L. Gelmini et al., Glucose-lowering properties of vanadium compounds: comparison of coordination complexes with maltol or kojic acid as ligands, Journal of Inorganic Biochemistry, vol. 68, no. 2, pp. 109-116, 1997.
62. F. Ai, Y. Ma, J. Wang, and Y. Li, Preparation, physicochemical characterization and in-vitro dissolution studies of diosmincyclodextrin inclusion complexes, Iranian Journal of Pharmaceutical Research, vol. 13, no. 4, pp. 1115-1123, 2014.
63. F. Hernandez Hernandez, J. Medina Escriche, and M. T. Gasco Andreu, Enhancement of the fluorescence of the zinc-morin complex by a non-ionic surfactant, Talanta, vol. 33, no. 6, pp. 537-540, 1986.
64. J. L. Nieto and A. M. Gutierrez, 1H NMR spectra at 360 MHz of diosmin and hesperidin in DMSO solution, Spectroscopy Letters, vol. 19, no. 5, pp. 427-434, 1986.
65. R. K. Markhamand, V. M. Chari, Carbon-13NMRspectroscopy of flavonoids, in The Flavonoids, pp. 19-134, Springer, New York, NY, USA, 1982.
66. D. A. Scott and A. M. Fisher, The insulin and the zinc content of normal and diabetic pancreas,The Journal of Clinical Investigation, vol. 17, no. 6, pp. 725-728, 1938.
67. L. Pari and S. Srinivasan, Antihyperglycemic effect of diosmin on hepatic key enzymes of carbohydratemetabolism in streptozotocin-nicotinamide-induced diabetic rats, Biomedicine and Pharmacotherapy, vol. 64, no. 7, pp. 477-481, 2010.
68. M. J. Reed, K. Meszaros, L. J. Entes et al., A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat, Metabolism, vol. 49, no. 11, pp. 1390-1394, 2000.
69. M. A. Abdul-Ghani, D. Tripathy, and R. A. DeFronzo, Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose, Diabetes Care, vol. 29, no. 5, pp. 1130-1139, 2006.
70. D. Jain, M. K. Bansal, R. Dalvi, A. Upganlawar, and R. Somani, Protective effect of diosmin against diabetic neuropathy in experimental rats, Journal of Integrative Medicine, vol. 12, no. 1, pp. 35-41, 2014.
71. B. A. Pederson, J. M. Schroeder, G. E. Parker, M. W. Smith, A. A. DePaoli-Roach, and P. J. Roach, Glucose metabolism in mice lacking muscle glycogen synthase, Diabetes, vol. 54, no. 12, pp. 3466-3473, 2005.
72. E. H. Harris, Elevated liver function tests in type 2 diabetes, Clinical Diabetes, vol. 23, no. 3, pp. 115-119, 2005.
73. N. H. Cho, H. C. Jang, H. C. Sung et al., Abnormal liver function test predicts type 2 diabetes: a community-based prospective study, Diabetes Care, vol. 30, no. 10, pp. 2566-2568, 2007.
74. N. Moller and K. S. Nair, Diabetes and protein metabolism, Diabetes, vol. 57, no. 1, pp. 3-4, 2008.